If any more evidence were needed of a bounceback in venture financing for biotechs after a dip in 2023, the $400 million first round just announced by Mirador Therapeutics should suffice.

Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus ...

Mirador Therapeutics has announced its launch after securing more than $400m from leading life sciences investors. It will focus on developing precision medicines for immune-mediated inflammatory ...

Yesterday, the company announced a new R&D partnership with precision medicine company Mirador Therapeutics, granting the biotech a license to use a "targeted set of aggregated, de-identified ...

The company has collaboration with Mirador Therapeutics to advance mirador’s precision medicines for immunology and inflammation. 23andMe Holding Co. was founded in 2006 and is headquartered in ...